Opendata, web and dolomites

Cells in Matrix SIGNED

Cells in Matrix – an innovative 3D model for R&D of Diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Cells in Matrix project word cloud

Explore the words cloud of the Cells in Matrix project. It provides you a very rough idea of what is the project "Cells in Matrix" about.

added    model    accelerating    hampered    prevalence    drugs    pharma    innovative    action    3d    drug    ing    demand    least    engineered    share    toxicology    vitro    betalin    adults    2019    matrix    compound    producing    reliability    human    11    x4    validation    keeps    billion       predictability    significantly    constant    13    saving    develops    identification    commercialization    culture    disruptive    offers    creates    function    revenues    rate    boehringer    stakeholders    direct    cells    tool    external    therapeutics    sourced    2045    entry    extended    global    discovery    compounds    reached    2017    poor    investment    molecules    endusers    fti    medications    people    diabetes    rendering    ingelheim    industry    20    emp    till    pharmacokinetics    academia    reaching    629    companies    adult    screening    cagr    commercial    kugelmeiers    90    gained    organ    fundraising    425    plans    insulin    life    cell    receives    mode    million    prediction    pancreas    micro    shelf    penetration    market   

Project "Cells in Matrix" data sheet

The following table provides information about the project.

Coordinator
BETALIN THERAPEUTICS LTD 

Organization address
address: 3 MENACHEM BEGIN
city: RAMAT GAM
postcode: 5268101
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙340˙842 €
 EC max contribution 2˙640˙417 € (79%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BETALIN THERAPEUTICS LTD IL (RAMAT GAM) coordinator 1˙233˙750.00
2    UNIVERSITAT ZURICH CH (ZURICH) participant 527˙967.00
3    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 478˙125.00
4    KUGELMEIERS AG CH (ERLENBACH) participant 400˙575.00

Map

 Project objective

The demand for diabetes drugs keeps increasing as adult Diabetes prevalence reached 425 million people in 2017 (1 in 11 adults) and is estimated to rise to 629 million till 2045. The market of Diabetes drugs is expected to reach €80.5 Billion in 2019 while the investment in Diabetes drug development is ~ €4 Billion (CAGR of 13%). There is a constant need for more effective diabetes medications, hampered by the poor predictability of the current systems for identification of lead compounds during drug discovery. The failure rate of new drugs development is about 90% and the cost for reaching the market with a new drug is ~ €1 Billion. Cells in Matrix Project develops an innovative 3D model for R&D of Diabetes Drugs , an Engineered Micro Pancreas (EMP) based on organ-derived 3D cell culture and human sourced insulin producing cells as an innovative tool for accelerating and cost reduction of Diabetes drug development. EMP system offers significantly extended shelf life and function for in-depth studies of drug molecules mode of action, validation, toxicology and in vitro pharmacokinetics, rendering higher prediction reliability. Cells in Matrix disruptive technology creates market added value to all the stakeholders, especially pharma industry, by improving compound screening at least X4 (from 5% rate of success today to at least 20%), resulting in cost saving that could reach €100 million per innovative new drug development. The project receives strong interest from stakeholders and plans immediate commercialization of the product to direct endusers, including academia and pharma companies, such as Boehringer Ingelheim. The FTI funding will enable market entry and validation & support external fundraising for the wider penetration of the global drug discovery market. Betalin Therapeutics and Kugelmeiers, the project commercial leading partners will share the growth and revenues gained by its commercial success.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CELLS IN MATRIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CELLS IN MATRIX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

Bio-LP-1 (2020)

A novel rapid environmental test for the human pathogen Legionella

Read More  

SAMBAfun (2018)

System for AcceleroMeter-Based Assessment of cardiac FUNction

Read More  

PATH-TOX (2018)

Artificial Intelligence to transform Drug and Chemical safety testing

Read More